The University of Chicago Header Logo

Connection

Girish Venkataraman to Antineoplastic Agents

This is a "connection" page, showing publications Girish Venkataraman has written about Antineoplastic Agents.
Connection Strength

0.244
  1. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023 08 15; 29(16):3151-3161.
    View in: PubMed
    Score: 0.100
  2. Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021 02 18; 11(2):39.
    View in: PubMed
    Score: 0.084
  3. Bone marrow with gelatinous transformation associated with residual disease in imatinib mesylate-treated chronic myelogenous leukaemia (CML). Pathology. 2012 Jan; 44(1):59.
    View in: PubMed
    Score: 0.045
  4. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016 Oct 18; 7(42):68833-68841.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.